Skip to main content

Table 1 Patient’s characteristics

From: The effect of intra-nasal tetra sodium pyrophosphate on decreasing elevated nasal calcium and improving olfactory function post COVID-19: a randomized controlled trial

Character Sodium chloride TSPP p (Fisher exact probability test)
Sample size, n 32 32
Age (years), mean ± SD 37.98 ± 6.27 36.87 ± 5.25
Days since symptoms to enrollment, mean ± SD 96.54 ± 4.12 94.81 ± 3.89
Gender
 Male, n 14 12 0.79
 Female, n 18 20 0.79
Smokers (current/never), n 5/32 4/32 1.00
Comorbidities, n
 Asthma 4 5 1.00
 Diabetes 2 4 0.67
 Hypertension 3 3 1.00
 Migraine 4 5 1.00
 Hyperuricemia 2 3 1.00
Current medication
 Anti-histamine 4 5 1.00
 Metformin 1 2 1.00
 Glimepiride 1 2 1.00
 ACE inhibitor 3 3 1.00
 Paracetamol 4 5 1.00